May 17, 2020

Bristol Myers suspends mid-stage trial of hepatitis C drug

Global bio-pharmaceutical company
experimental hepatitis C
Admin
2 min
Bristol Myers suspends mid-stage trial of experimental hepatitis C drug
Global bio-pharmaceutical company Bristol Myers Squibb Co has suspended a mid-stage trial of an experimental hepatitis C drug it secured in its $2.5 bi...

Global bio-pharmaceutical company Bristol Myers Squibb  Co has  suspended a mid-stage trial of an experimental hepatitis C drug  it secured in its $2.5 billion buyout of Inhibitex Inc after one patient  developed heart failure.

 The New York-based drug maker said it has suspended the clinical trial of the drug known as BMS-986094 as a concern for safety.  

The drug maker has stopped the administration of the drug to about 30 patients who were a part of the Phase 2b study.  The heart failure occurred in a patient who received the highest daily dose of 200 miligrams.

Sonia Choi, a Bristol-Myers spokeswoman said, “Although the issue presented in a patient receiving that dose, it doesn’t preclude the possibility of issues with other doses.” Sonia also said, “At this point, we don’t know what the cause of the safety issue is. We are taking time to evaluate information on all patients receiving this compound.” 

The global pharma company has used acquisitions to get new experimental medicines as it aims to replace the loss of revenue from Plavix, a blood thinner which generated 33%  of 2011 sales. Bristol Myers is also competing with  other drug company Gilead Sciences Inc  to get clearance of the new generation of medicines to treat  the estimated 170 million patients with hepatitis C.

Bristol Myers Squibb is a pharmaceutical company formed through the merger of its predecessors Bristol-Myers and the Squibb Corporation. 

Share article

Jun 21, 2021

Dubai's new smart neuro spinal hospital: need to know

Robotics
smarthospitals
Cancer
Neurology
2 min
The brand new Neuro Spinal Hospital and Radiosurgery Centre has opened in Dubai. We take a look at what this smart hospital offers. 

We take a look at Dubai's new smart hospital. 

What: The Neuro Spinal Hospital and Radiosurgery Centre is a new hospital featuring state-of-the-art technology for spinal, neurosurgical, neurological, orthopaedic, radiosurgery and cancer treatments. The 700 million AED hospital, (equivalent to £138 million), has 114 beds, smart patient rooms, and green spaces for patient rehabilitation, and is four times the capacity of its former premises in Jumeirah.   It is also the UAE’s first hospital to have surgical robots. 

Where: The hospital is located in the Dubai Science Park. Founded in 2005,  Dubai Science Park is home to more than 350 companies from multinational corporations in life sciences, biotechnology and research; over 4,000 people work here each day. 

Who: The UAE's Neuro Spinal Hospital and Radiosurgery Centre was first established in Jumeirah in 2002 by Dr. Abdul Karim Msaddi, as the first as the first "super-specialty" neuroscience hospital. 

Why: With advanced diagnosis and robotics, the hospital will provide care across neuroscience, spine, orthopaedics and oncology for people residing in the UAE, as well as international patients.  

Prof. Abdul Karim Msaddi, Chairman and Medical Director of the hospital, said: “We are proud to bring world-class healthcare services to Dubai and believe our  next-generation hospital will be a game-changer for the emirate’s and the region’s medical industry.

"It will not only significantly increase the availability of specialist neuroscience and radiosurgery treatments and provide better patient care but help attract and develop local and international talent. Investing in the new centre represents our continued faith in the resilience of the region’s economy, as well as a testament to our ongoing drive towards healthcare innovation in the UAE.”

Share article